ClinicalTrials.gov
ClinicalTrials.gov Menu

EndoBarrier® SANS™ in Over-weight or Obese Type 2 Diabetic Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02443753
Recruitment Status : Terminated
First Posted : May 14, 2015
Last Update Posted : February 10, 2016
Sponsor:
Collaborator:
University of Malaya
Information provided by (Responsible Party):
GI Dynamics

Brief Summary:
This study will evaluate the safety and efficacy of the EndoBarrier® SANS™ in overweight and obese subjects with type 2 diabetes. The barbless second generation device is being developed as a means to reduce the incidence of adverse events associated with the barbs of the predicate device while maintaining a similar efficacy profile as measured by changes in weight and diabetic endpoints (HbA1c, blood glucose, insulin, etc.). This first use in human will primarily evaluate preliminary safety, tolerability and efficacy of the new design. Because of the new design and its first study in human subjects, only a 3 month implant duration will be evaluated in this study.

Condition or disease Intervention/treatment Phase
Obesity Type 2 Diabetes Device: EndoBarrier SANS Not Applicable

Detailed Description:

The GI Dynamics' EndoBarrier® SANS™ is an endoscopically positioned device that represents an alternative to the use of gastric bypass operative techniques as a means of re-routing food and altering the gut-hormone axis. The EndoBarrier® SANS™ provides an alternate passage of chime through the duodenum and proximal sixty centimeters of jejunum replicating in part the bypass of bariatric surgery.

This study will be conducted at a single clinical site in Malaysia. Approximately 16 subjects will be enrolled in two cohorts of 8 subjects. The two cohorts will be implanted one week apart with the implantation of the second cohort triggered by the absence of major technical or clinical issues (i.e. safety, tolerability) observed in the first cohort in the first seven days.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Safety and Tolerability Study of the Use of the EndoBarrier® SANS™ in Over-weight or Obese Type 2 Diabetic Subjects
Study Start Date : May 2015
Actual Primary Completion Date : July 2015
Actual Study Completion Date : July 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Body Weight

Arm Intervention/treatment
Experimental: Device
Subjects who receive the device
Device: EndoBarrier SANS
Eligible subjects will be implanted with the EndoBarrier® SANS™ Device for a period of 3 months. The GI Dynamics' EndoBarrier® SANS™ is an endoscopically positioned device that represents an alternative to the use of gastric bypass operative techniques as a means of re-routing food and altering the gut-hormone axis. The EndoBarrier® SANS™ provides an alternate passage of chime through the duodenum and proximal sixty centimeters of jejunum replicating in part the bypass of bariatric surgery.




Primary Outcome Measures :
  1. Safety and Tolerability will be evaluated as the incidence of AEs and SAEs/UADEs. [ Time Frame: 3 months ]
    Safety will be evaluated as the incidence of AEs and SAEs/UADEs.


Secondary Outcome Measures :
  1. Efficacy as measured by Change in Body weight [ Time Frame: 3 months ]
    Change in Body weight

  2. Efficacy as measured by Percent excess weight loss [ Time Frame: 3 months ]
    Percent excess weight loss

  3. Efficacy as measured by Change in HbA1c (%) [ Time Frame: 3 months ]
    Change in HbA1c (%)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age > 21 years and < 65 years - male or female
  • Overweight or obese individuals (BMI ≥ 27 kg/m2 and ≤ 40 kg/m2)
  • Diagnosed with Type 2 diabetes and being treated by diet or oral agents (metformin, SU, DPP-4i, or TZD)
  • Glycemic state: HbA1c at screening 7.0-10.0%.
  • History of failure with non-surgical weight loss methods
  • Subjects willing to comply with study requirements
  • Subjects who have signed an informed consent form

Exclusion Criteria:

Diabetic subjects requiring injectable treatments (insulin, GLP-1R agonists)

  • Subjects requiring anticoagulation therapy
  • Subjects with iron deficiency and iron deficiency anemia
  • Condition of the gastrointestinal tract, such as ulcers or inflammatory bowel disease
  • Treatment represents an unreasonable risk to the subject
  • Known history of acute or chronic pancreatitis
  • Known history of organ failure (i.e. renal insufficiency, heart failure, fibrotic / cirrhotic liver disease, or pulmonary disease)
  • Symptomatic coronary artery disease or pulmonary dysfunction
  • Subjects with known symptomatic biliary disease
  • Known infection at the time of implant
  • Severe coagulopathy, upper gastro-intestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasia
  • Congenital or acquired anomalies of the GI tract such as atresias or stenoses
  • Pregnant or has the intention of becoming pregnant in the next 6 months
  • Unresolved alcohol or drug addiction
  • HIV positive subjects
  • Subjects with hepatitis B or C
  • Currently taking the following medications within 30 days of implant:

systemic corticosteroids, drugs known to affect GI motility, prescription or over the counter weight loss medications such as Sibutramine hydrochloride monohydrate and Orlistat

  • Allergy or hypersensitivity to ceftriaxone, cephalosporins, penicillin, and all equivalent antibiotics
  • Any characteristics which, in the opinion of the investigator, makes the subject a poor candidate for device placement in this clinical trial
  • Previous GI surgery that could affect the ability to place the liner or the function of the implant.
  • Subjects unable to discontinue NSAIDs (non-steroidal anti-inflammatory drugs) during the implant period
  • H. pylori positive subjects (Note: patients may be enrolled if they had a prior history and were successfully treated).
  • Family or subject history of a known diagnosis or pre-existing symptoms of systemic lupus erythematosus, scleroderma or other autoimmune connective tissue disorder
  • Unable to tolerate proton pump inhibitors
  • Participating in another ongoing investigational clinical trial that is ongoing or within 3 months of the implant date
  • Positive stool guaiac at time of screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02443753


Locations
Malaysia
Universiti Malaya Medical Centre, Jalan universiti
Kuala Lumpur, Malaysia, 50603
Sponsors and Collaborators
GI Dynamics
University of Malaya
Investigators
Principal Investigator: Eng Hong Pok, MD University of Malaya
Principal Investigator: Wah Kheong Chan, MD University of Malaya

Responsible Party: GI Dynamics
ClinicalTrials.gov Identifier: NCT02443753     History of Changes
Other Study ID Numbers: 15-1
First Posted: May 14, 2015    Key Record Dates
Last Update Posted: February 10, 2016
Last Verified: February 2016

Additional relevant MeSH terms:
Overweight
Body Weight
Signs and Symptoms